Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on RHI Magnesita

(Sharecast News) - Analysts at Berenberg hiked their target price on RHI Magnesita from 4,150.0p to 4,400.0p on Wednesday, noting that the group's recent acquisition of Resco had provided it with better US access. Berenberg thinks that the near-term restructuring from the acquisition will have an impact on its forecasts. However, it also expects upside from this decision over time, as footprint efficiencies and supply chain streamlining come through, helped by Resco's US focus serving to improve RHI Magnesita's US manufacturing base.

The German bank updated its forecasts to include the acquisition of Resco in 2025, resulting in a 4-6% upgrade to its 2025 and 2026 forecasts.

Berenberg also acknowledged that the outlook was changeable and expect that the group's guidance at its FY24 results in a few weeks will likely "keep a lid on expectations" for the moment but it also noted that it includes little in the way of medium-term synergies in its forecasts, so said upside risk remains over time.

"RHI Magnesita trades on 7.5x 2025 P/E. Our new 4,400.0p target price reflects our 10x 2025 P/E for this stock and we maintain our 'buy' rating," said Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.